- Home
- MPU vs NRXP Comparison
MPU vs NRXP Comparison
Compare MPU & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- NRXP
- Stock Information
- Founded
- MPU 1989
- NRXP 2015
- Country
- MPU Singapore
- NRXP United States
- Employees
- MPU N/A
- NRXP N/A
- Industry
- MPU Transportation Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MPU Consumer Discretionary
- NRXP Health Care
- Exchange
- MPU Nasdaq
- NRXP Nasdaq
- Market Cap
- MPU 35.5M
- NRXP 32.6M
- IPO Year
- MPU 1998
- NRXP N/A
- Fundamental
- Price
- MPU $0.96
- NRXP $3.50
- Analyst Decision
- MPU
- NRXP Strong Buy
- Analyst Count
- MPU 0
- NRXP 4
- Target Price
- MPU N/A
- NRXP $28.50
- AVG Volume (30 Days)
- MPU 331.4K
- NRXP 295.0K
- Earning Date
- MPU 08-13-2025
- NRXP 08-13-2025
- Dividend Yield
- MPU N/A
- NRXP N/A
- EPS Growth
- MPU N/A
- NRXP N/A
- EPS
- MPU N/A
- NRXP N/A
- Revenue
- MPU $35,228,600.00
- NRXP N/A
- Revenue This Year
- MPU N/A
- NRXP N/A
- Revenue Next Year
- MPU N/A
- NRXP N/A
- P/E Ratio
- MPU N/A
- NRXP N/A
- Revenue Growth
- MPU N/A
- NRXP N/A
- 52 Week Low
- MPU $0.49
- NRXP $1.10
- 52 Week High
- MPU $1.98
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- MPU 56.48
- NRXP 66.15
- Support Level
- MPU $0.77
- NRXP $2.90
- Resistance Level
- MPU $1.15
- NRXP $3.61
- Average True Range (ATR)
- MPU 0.08
- NRXP 0.28
- MACD
- MPU 0.01
- NRXP -0.03
- Stochastic Oscillator
- MPU 51.16
- NRXP 64.59
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.